Table 1. The most common clinical findings in piperazine treated group (n = 20) and D_oraTG (n = 20).

Groups	Follow up period	Anorexia	Signs of Dehydration	Pale mms (conjunctiva)	CRT (1–2 s)1	Ataxia	Abnormal lung sound	Cough	Diarrhoea	Normal LNs
PipTG	Day 0a	0 (0)b	8 (40.00)	14 (70.00)	11 (55.00)	0 (0)	0 (0)	0 (0)	0 (0)	20 (100)
	Day 7	0 (0)	6 (30.00)	8 (40.00)	11 (55.00)	0 (0)	0 (0)	0 (0)	0 (0)	20 (100)
	Day 14	0 (0)	5 (25.00)	8 (40.00)	13 (65.50)	0 (0)	0 (0)	0 (0)	0 (0)	20 (100)
	Day 21	0 (0)	3 (15.00)	5 (25.00)	15 (75.00)	0 (0)	0 (0)	0 (0)	0 (0)	20 (100)
	Day 28	0 (0)	3 (15.00)	3 (15.00)	15 (75.00)	0 (0)	0 (0)	0 (0)	0 (0)	20 (100)
DoraTG	Day 0a	0 (0)	10 (50.00)	12 (60.00)	13 (65.00)	0 (0)	0 (0)	0 (0)	0 (0)	20 (100)
	Day 7	0 (0)	8 (40.00)	6 (30.00)	14 (70.00)	0 (0)	0 (0)	0 (0)	0 (0)	20 (100)
	Day 14	0 (0)	7 (35.00)	3 (15.00)	17 (85.00)	0 (0)	0 (0)	0 (0)	0 (0)	20 (100)
	Day 21	0 (0)	4 (20.00)	3 (15.00)	18 (90.00)	0 (0)	0 (0)	0 (0)	0 (0)	20 (100)
	Day 28	0 (0)	3 (15.00)	2 (10.00)	18 (90.00)	0 (0)	0 (0)	0 (0)	0 (0)	20 (100)

Reference values according to Gore et al. (2008).

P_ipTG = piperazine treated group; D_oraTG = doramectin treated group; CRT = capillary refill time; MMs = mucous membranes; LNs = lymph nodes.

^aTreatment day.

^bNumber of donkeys (%).